Inhibikase Therapeutics (IKT) Net Cash Flow (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Net Cash Flow data on file, last reported at -$89.6 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$89.6 million, down 628.86% year-over-year; the trailing twelve-month figure through Mar 2026 was -$23.9 million (down 133.58% YoY), and the FY2025 annual result was $82.7 million, up 74.81% from the prior year.
• Net Cash Flow slipped to -$89.6 million in Q1 2026 per IKT's latest filing, from $101.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $101.0 million in Q4 2025 and troughed at -$89.6 million in Q1 2026.
• A 5-year average of $519022.2 and a median of -$2.2 million in 2024 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2024 and 2025: Net Cash Flow surged 1075.7% in 2024, then slumped 1716.49% in 2025.
• A 5-year view of Net Cash Flow shows it stood at $1.4 million in 2022, then sank by 504.95% to -$5.7 million in 2023, then surged by 1075.7% to $55.6 million in 2024, then soared by 81.64% to $101.0 million in 2025, then tumbled by 188.8% to -$89.6 million in 2026.
• Business Quant data shows IKT's Net Cash Flow at -$89.6 million in Q1 2026, $101.0 million in Q4 2025, and -$39.5 million in Q3 2025.